Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma
To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).
Hodgkin's Lymphomas
BIOLOGICAL: MDX-1401
Safety and Tolerability Profile, Two years
Objective Response Rate (ORR), Day 50|Tumor response assessment, Two year
To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).